Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP014: Transmural healing is better than mucosal healing in Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Raimundo Fernandes S.*1, Vale Rodrigues R.2, Bernardo S.1, Cortez Pinto J.2, Rosa I.2, Correia L.1, Moura Santos P.3, Rita Gonçalves A.3, Valente A.3, Baldaia C.3, Pereira da Silva J.2, Dias Pereira A.2, Velosa J.1

1Hospital de Santa Maria, Serviço de Gastrenterologia e Hepatologia, Lisboa, Portugal 2Instituto Português de Oncologia de Lisboa, Serviço de Gastrenterologia, Lisboa, Portugal 3Centro Hospitalar Lisboa Norte, Gastrenterology, Lisbon, Portugal

DOP015: International differences in gastroenterologists' perspective on stopping therapy for patients with Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Siegel C.A.*1, Thompson K.D.1, Walls D.2, Gollins J.3, Colombel J.-F.4, Louis E.5 on behalf of the BIOCYCLE Group5

1Dartmouth-Hitchcock Medical Center, Lebanon, United States 2BDJ Solutions, Boston, United States 3Delta Modelling, Chicago, United States 4Icahn School of Medicine at Mount Sinai, New York, United States 5University Hospital CHU of Liège, Liège, Belgium

DOP016: Long-term safety of in utero exposure to anti-tumor necrosis factor for the treatment of inflammatory bowel diseases: results from the multicenter European TEDDY studyECCO '17 Barcelona
Year: 2017
Authors:

Chaparro M.*1, Verreth A.2, Lobaton T.3, Gravito-Soares E.4, Julsgaard M.5, Savarino E.6, Magro F.7, Avni Biron I.8, Lόpez-Serrano P.9, Casanova M.1, Gompertz M.10, Vitor S.11, Arroyo M.12, Pugliese D.13, Zabana Y.14, Vicente R.15, Aguas M.16, Bar-Gil Shitrit A.17, Gutierrez A.18, Doherty G.19, Fernández-Salazar L.20, Martinez Cadilla J.21, Huguet J.22, O'Toole A.23, Stasi E.24, Manceñido Marcos N.25, Villoria A.26, Karmiris K.27, Rahier J.28, Rodriguez C.29, Diz-Lois Palomares M.30, Fiorino G.31, Benítez J.32, Principi M.33, Naftali T.34, Taxonera C.35, Mantzaris G.36, Sebkova L.37, Iade B.38, Lissner D.39, Ferrer Bradley I.40, Lόpez-San Román A.41, Marín-Jiménez I.42, Merino O.43, Sierra M.44, Van Domselaar M.45, Caprioli F.46, Guerra I.47, Peixe P.48, Piqueras M.49, Rodríguez-Lago I.50, Ber Y.51, Van Hoeve K.2, Torres P.3, Gravito-Soares E.4, Rudbeck-Thomsen D.5, Bartolo O.6, Peixoto A.7, Martín G.8, Pérez J.1, Garre A.1, Donday M.G.1, Martín de Carpi J.52, Gisbert J.P.1 Gastroenterology Units, on behalf of the TEDDY Study Group Investigators

1Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Madrid, Spain 2University Hospitals Leuven, Leuven, Belgium 3Hospital Universitari Germans Trias i Pujol, Badalona, Spain 4Centro Hopitalar e Universitario de Coimbra, Coimbra, Portugal 5Aarhus University Hospital, Aarhus, Denmark 6University of Padua, Padua, Italy 7Centro Hospitalar Sao Joao, Porto, Portugal 8Rabin Medical Center, Petaj Tikva, Israel 9Hospital Universitario Fundaciόn Alcorcόn, Alcorcόn, Spain 10Hospital Clinic Barcelona, Barcelona, Spain 11Hospital de Santa Maria de Lisboa, Lisboa, Portugal 12Hospital Clínico de Zaragoza, Zaragoza, Spain 13Complesso Integrato Columbus Catholic University, Roma, Italy 14Hospital Universitari Mútua de Terrassa, Terrassa, Spain 15Hospital Universitario Miguel Servet, Zaragoza, Spain 16Hospital Universitario La Fe, Valencia, Spain 17Shaare Zedek Medical Center Jerusalem, Jerusalem, Israel 18Hospital General Universitario de Alicante, Alicante, Spain 19St. Vincents University Hospital, Dublin, Ireland 20Hospital Clínico Universitario de Valladolid, Spain, Valladolid, Spain 21Hospital Universitario Alvaro Cunqueiro, Vigo, Spain 22Hospital General Universitario de Valencia, Valencia, Spain 23Beaumont Hospital, Dublin, Ireland 24IRCCS Saverio de Bellis, Castellana Grotte, Italy 25Hospital Infanta Sofía, Madrid, Spain 26Hospital Parc Taulí, Sabadell, Spain 27Venizeleio General Hospital, Heraklion, Greece 28CHU Dinant Godinne, Dinant, Belgium 29Complejo Universitario de Navarra, Pamplona, Spain 30Hospital Universitario A Coruña, Coruña, Spain 31Humanitas Research Hospital, Milan, Italy 32Hospital Reina Sofia, Cόrdoba, Spain 33Azienda Ospedaliera Policlinico de Bari, Bari, Italy 34Meir Hospital Kfar saba Tel Aviv University, Tel Aviv, Israel 35Hospital Clínico San Carlos, Madrid, Spain 36Evangelismos, Ophthalmiatreion Athinon and Polyclinic Hospitals, Athens, Greece 37Azienda Ospedaliera “Pugliese-Ciaccio”, Catanzaro, Italy 38Hospital de Clínicas, Montevideo, Uruguay 39Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany 40Hospital de Manises, Manises, Spain 41Hospital Ramόn y Cajal, Madrid, Spain 42Hospital General Universitario Gregorio Marañon, Madrid, Spain 43Hospital Universitario de Cruces, Baracaldo, Spain 44Hospital de Leόn, Leόn, Spain 45Hospital de Torrejόn, Torrejόn de Ardoz, Spain 46IRCCS Ospedale Ca Granda Policlinico di Milano, Milano, Italy 47Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain 48Centro Hospitalar Lisboa Ocidental, Lisboa, Portugal 49Consorci Sanitari de Terrasa, Terrasa, Spain 50Hospital de Galdakao, Vizcaya, Spain 51Hospital San Jorge, Huesca, Spain 52Hospital Sant Joan de Déu, Barcelona, Spain

DOP017: Patterns of anti-TNF use and associated treatment outcomes in inflammatory bowel disease patients: results from an analysis of Dutch health insurance claims dataECCO '17 Barcelona
Year: 2017
Authors:

Bots S.*1, Hoekman D.1,2, Benninga M.2, Ponsioen C.1, Smeets H.3, D'Haens G.1, Löwenberg M.1

1Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, Netherlands 2Academic Medical Center (AMC), Department of Pediatric Gastroenterology and Nutrition, Amsterdam, Netherlands 3Achmea Health Insurance, Amersfoort, Netherlands

DOP018: Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADAECCO '17 Barcelona
Year: 2017
Authors:

Travis S.*1, Feagan B.2, Peyrin-Biroulet L.3, Panaccione R.4, Danese S.5, Lazar A.6, Robinson A.7, Thakkar R.7, Pappalardo B.7, Petersson J.7, Bereswill M.6, Chen N.7, Skup M.7

1Oxford University Hospitals, Oxford, United Kingdom 2Robarts Research Institute, London, Canada 3University Hospital of Nancy, Les Nancy, France 4University of Calgary, Calgary, Canada 5Istituto Clinico Humanitas, Milan, Italy 6AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany 7AbbVie Inc., North Chicago, United States

DOP019: Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn's disease: a GEMINI 2 post hoc analysisECCO '17 Barcelona
Year: 2017
Authors:

Feagan B.G.*1, Sandborn W.J.2, Colombel J.-F.3, O'Byrne S.4, Khalid J.M.5, Brayshaw N.6, Geransar P.7, Rubin D.T.8

1Robarts Research Institute, University of Western Ontario, Robarts Clinical Trials Inc, London, Canada 2University of California San Diego, Division of Gastroenterology, La Jolla, United States 3Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States 4Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, United Kingdom 5Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom 6Takeda Development Centre Europe Ltd, Global Statistics and Statistical Programming, London, United Kingdom 7Takeda Pharmaceuticals International AG, Global Medical Affairs, Zürich, Switzerland 8University of Chicago Medicine Inflammatory Bowel Disease Center, Section of Gastroenterology, Hepatology, and Nutrition, Chicago, United States

DOP020: Higher vedolizumab levels are associated with deep remission in patients with Crohn's disease and ulcerative colitis on maintenance therapy with vedolizumabECCO '17 Barcelona
Year: 2017
Authors:

Yarur A.*1, Bruss A.1, Jain A.2, Kondragunta2 V.2, Hester K.2, Luna T.2, Agrawal D.1, Patel A.1, Fox C.1, Werner S.1, Naik S.2, Stein D.1

1Medical College of Wisconsin, Gastroenterology and Hepatology, Milwaukee, United States 2Prometheus Laboratories, San Diego, United States

DOP021: Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension studyECCO '17 Barcelona
Year: 2017
Authors:

Vermeire S.*1, Loftus E.V.2, Colombel J.-F.3, Feagan B.4, Sandborn W.5, Sands B.6, Danese S.7, D'Haens G.8, Kaser A.9, Panaccione R.10, Rubin D.11, Shafran I.12, O'Byrne S.13, Geransar P.13, Previtali A.14, Khalid J.M.15, Kaviya A.16

1University Hospitals Leuven, Dpt of Gastroenterology, Leuven, Belgium 2Mayo Clinic College of Medicine, Gastroenterology and Hepatology, Rochester, United States 3Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States 4Robarts Research Institute, University of Western Ontario, Robarts Clinical Trials, London, Canada 5University of California - San Diego, Division of Gastroenterology, La Jolla, United States 6Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States 7Humanitas University, Italy, Gastrointestinal Immunopathology, Milan, Italy 8Academic Medical Centre, Dept. of Gastroenterology, Amsterdam, Netherlands 9University of Cambridge, Division of Gastroenterology and Hepatology, Cambridge, United Kingdom 10University of Calgary, Department of Medicine, Calgary, Canada 11University of Chicago Medicine Inflammatory Bowel Disease Center, Section of Gastroenterology, Hepatology, and Nutrition, Chicago, United States 12Shafran Gastroenterology Research center, Gastroenterology, Winter Park, United States 13Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, Switzerland 14Takeda Development Centre Europe Ltd, Global Statistics and Statistical Programming, London, United Kingdom 15Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom 16Takeda Development Centre Europe Ltd, Clinical Development, London, United Kingdom

DOP022: Vedolizumab and anti-TNFα treatment effectiveness in patients with IBD treated in Germany: a retrospective chart reviewECCO '17 Barcelona
Year: 2017
Authors:

Ehehalt R.*1, Schubert S.2, Stein D.3, Lambrelli D.4, Bassel M.5, Orzechowski H.-D.6, Minda K.7, Khalid J.M.8

1Gastroenterology Outpatient Clinic, Heidelberg, Germany 2Gastroenterologist in Private Practice, Berlin, Germany 3Evidera, Montreal, Canada 4Evidera, Hammersmith, United Kingdom 5UBC: An Express Scripts Company, Montreal, Canada 6Takeda Pharma GmbH, Berlin, Germany 7Takeda Pharmaceuticals International AG, Zurich, Switzerland 8Takeda Development Centre Europe Ltd, London, United Kingdom

DOP023: Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortiumECCO '17 Barcelona
Year: 2017
Authors:

Dulai P.*1, Meserve J.1, Hartke J.2, Chilukuri P.2, Chaudrey K.3, Koliani-Pace J.L.4, Kochhar G.5, Parikh M.P.5, Shmidt E.6, Hirten R.6, Luo M.7, Barocas M.7, Lasch K.7, Sultan K.8, Swaminath A.9, Bohm M.10, Lukin D.11, Hudesman D.12, Shen B.5, Siegel C.A.4, Sands B.E.6, Colombel J.-F.6, Kane S.3, Loftus Jr. E.V.3, Singh S.1, Sandborn W.J.1, Boland B.S.1

1University of California - San Diego, La Jolla, United States 2Indiana University School of Medicine, Indianapolis, United States 3Mayo Clinic, Rochester, United States 4Dartmouth-Hitchcock Medical Center, Lebanon, United States 5Cleveland Clinic Foundation, Cleveland, United States 6Icahn School of Medicine at Mount Sinai, New York, United States 7Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States 8North Shore University Hospital, Manhasset, United States 9Lenox Hill Hospital, New York, United States 10Indiana University Hospital, Indianapolis, United States 11Albert Einstein College of Medicine, Montefiore Medical Center, New York, United States 12New York University School of Medicine, New York, United States

DOP024: Vedolizumab clinical and post-marketing safety experience of opportunistic infectionsECCO '17 Barcelona
Year: 2017
Authors:

Ng S.C.*1, Palo W.2, Blake A.3, Rana-Khan Q.4, Bhayat F.5

1Chinese University of Hong Kong, Department of Medicine and Therapeutics, Hong Kong, Hong Kong 2Takeda Development Center Americas, Inc., Global Statistics and Statistical Programming, Deerfield, United States 3Takeda Development Center Europe Ltd, Global Pharmacovigilance, London, United Kingdom 4Takeda Pharmaceutical International AG Singapore, Emerging Markets Medical Affairs, Singapore, Singapore 5Takeda Development Centre Europe Ltd, Global Pharmacovigilance, London, United Kingdom

DOP025: Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a post-hoc analysis of the OBSERV-IBD cohort from the GETAIDECCO '17 Barcelona
Year: 2017
Authors:

Tadbiri S.*1, Grimaud J.C.2, Peyrin-Biroulet L.3, Filippi J.4, Pariente B.5, Roblin X.6, Buisson A.7, Stefanescu C.8, Trang-Poisson C.9, Altwegg R.10, Marteau P.11, Vaysse T.12, Bourrier A.13, Nancey S.14, Laharie D.15, Allez M.16, Bouhnik Y.8, Amiot A.17

1CHU Henri Mondor, Department of Gastroenterology, Creteil, France 2Hospital Nord, Department of Gastroenterology and Hepatology, Marseille, France 3CHU Nancy, Department of Gastroenterology and Hepatology, Vandoeuvre-Lès-Nancy, France 4Archet 2 Hospital, Department of Gastroenterology, Nice, France 5CHRU Lille, Department of Gastroenterology, Lille, France 6University of Saint Etienne, Department of Gastroenterology, Saint Etienne, France 7CHU Estaing, Department of Gastroenterology, Clermont-Ferrand, France 8APHP Beaujon, Department of Gastroenterology, Clichy, France 9CHU Hotel Dieu, Department of Gastroenterology, Nantes, France 10CHU Montpellier Saint Eloi Hospital, Department of Gastroenterology, Montpellier, France 11Hospital Lariboisière, Department of Gastroenterology, Paris, France 12CHU Bicêtre, Department of Gastroenterology, Le Kremlin-Bicêtre, France 13APHP St. Antoine Hospital, Department of Gastroenterology, Paris, France 14Hospital Edouard Herriot, Department of Gastroenterology and Hepatology, Lyon, France 15CHU Bordeaux, Department of Gastroenterology, Bordeaux, France 16Hospital Saint-Louis, Department of Gastroenterology, Paris, France 17Henri Mondor Hospital, Gastroenterology, Creteil, France

DOP026: Sustained remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis of week 14 remittersECCO '17 Barcelona
Year: 2017
Authors:

Stallmach A.*1, Bokemeyer B.2, Axler J.3, Curtis R.4, Ehehalt R.5, Feagan B.6, Geransar P.7, James A.8, Kaviya A.9, Khalid J.M.10, Wolf D.11, Schreiber S.12

1University hospital Jena, Department of Internal Medicine IV, Jena, Germany 2Gastroenterology Practice, Private practice, Minden, Germany 3TDDA (Toronto Digestive Disease Associates Inc.), Toronto, Canada 4Takeda Development Centre Europe Ltd, Global Medical Affairs, London, United Kingdom 5Praxis für Gastroenterologie, Gastroenterology, Heidelberg, Germany 6Robarts Research Institute, University of Western Ontario, Robarts Clinical Trials, London, Canada 7Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, Switzerland 8Takeda Development Centre Europe Ltd, Global Statistics and Statistical Programming, London, United Kingdom 9Takeda Development Centre Europe Ltd, Clinical Development, London, United Kingdom 10Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom 11Atlanta Gastroenterology Associates, Emory Saint Joseph's, Atlanta, United States 12University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany

DOP027: Long-term efficacy and safety of ustekinumab in refractory Crohn's disease patients: a multicenter retrospective experienceECCO '17 Barcelona
Year: 2017
Authors:

Wils P.*1, Bouhnik Y.2, Michetti P.3, Flourie B.4, Brixi H.5, Bourrier A.6, Allez M.7, Duclos B.8, Serrero M.9, Buisson A.10, Amiot A.11, Fumery M.12, Roblin X.13, Peyrin-Biroulet L.14, Filippi J.15, Bouguen G.16, Abitbol V.17, Coffin B.18, Simon M.19, Laharie D.20, Pariente B.1

1University of Lille 2, Department of Gastroenterology, Lille, France 2Beaujon Hospital, Gastroenterology Unit, Clichy, France 3University Hospital Lausanne, Division of Gastroenterology & Hepatology, Lausanne, Switzerland 4Centre Hospitalier Lyon-Sud, Service d'Hépato-gastro-entérologie, Lyon, France 5CHU de Reims, Gastroenterologie, Reims, France 6University Hospital of Saint Antoine, APHP, Gastroenterology, Paris, France 7APHP, Hopital Saint Louis, Department of Gastroenterology, Paris, France 8Université de Strasbourg, Gastroenterology, Strasbourg, France 9Hospital Nord Assistance Publique de Marseille, Department of Gastroenterology, Marseille, France 10Clermont-Ferrand University, Clermont-Ferrand, France 11Hospital Henri-Mondor, Department of Gastroenterology, Creteil, France 12Amiens University Hospital, Gastroenterology, Amiens, France 13University of Saint Etienne, Department of Gastroenterology, Saint Etienne, France 14CHU Nancy, Department of Gastroenterology, Nancy, France 15CHU de Nice, Department of Gastroenterology, Nice, France 16CHU Rennes, Department of HepatoBiliary Surgery and Digestive, Rennes, France 17Cochin University Hospital, Gastroenterology, Paris, France 18Hopital Louis-Mourier, Gastroenterologie, Colombes, France 19Institut Mutualiste Montsouris, Gastroenterology, Paris, France 20CHU de Bordeaux, Gastroenterology, Pessac, France

DOP028: Antibodies towards vedolizumab appear from week 2 onwards and disappear upon treatmentECCO '17 Barcelona
Year: 2017
Authors:

Bian S.*1, Tang H.T.1, Peeters M.1, Compernolle G.1, Dreesen E.1, Van Assche G.2, Ferrante M.2, Vermeire S.2, Gils A.1

1KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium 2University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium

DOP029: Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post-hoc analysis of the taxit trialECCO '17 Barcelona
Year: 2017
Authors:

Van Stappen T.*1, Vande Casteele N.1, Van Assche G.2, Ferrante M.2, Vermeire S.2, Gils A.1

1KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium 2UZ Leuven, Department of Clinical and Experimental Medicine, Leuven, Belgium

DOP030: Anti-TNF re-induction is as effective, simpler and cheaper compared with dose interval shortening following secondary loss of response in Crohn's disease: a dual centre “real world” studyECCO '17 Barcelona
Year: 2017
Authors:

Srinivasan A.*1, Vasudevan A.1,2,3, McFarlane A.1, Gibson P.2,3, Sparrow M.2,3, van Langenberg D.1,2

1Eastern Health, Gastroenterolgy, Melbourne, Australia 2Monash University, Melbourne, Australia 3Alfred Health, Gastroenterology, Melbourne, Australia

DOP031: Subtherapeutic serum infliximab trough levels and complete mucosal healing are associated with sustained clinical remission after infliximab discontinuation in paediatric Crohn's disease patientsECCO '17 Barcelona
Year: 2017
Authors:

Kang B.*1, Lee K.1, Kim K.2, Lee J.H.3, Choe Y.H.1

1Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Pediatrics, Seoul, South Korea 2Samsung Medical Center, Biostatistics and Clinical Epidemiology Center, Seoul, South Korea 3Chungbuk National University Hospital, Chungbuk National University College of Medicine, Department of Pediatrics, Cheongju, South Korea

DOP032: Hydrocortisone premedication withdrawal in patients on stable infliximab maintenance: clinical and pharmacokinetic outcomesECCO '17 Barcelona
Year: 2017
Authors:

Tran-Minh M.-L.*1, Maillet M.1, Auzolle C.1,2, Simon M.3, Cathala A.L.1, Aparicio T.1,2, Baudry C.1, Bonnet J.1, Lourenco N.1, Houze P.4, Gornet J.-M.1, Allez M.1,2

1Saint Louis Hospital, Gastroenterology, Paris, France 2INSERM, U940, Paris, France 3Institut Montsouris, Gastroenterology, Paris, France 4Saint Louis Hospital, Pharmacology, Paris, France

DOP033: Severely active ulcerative colitis is associated with high baseline infliximab clearance, reduced serum half-life and worse endoscopic outcomesECCO '17 Barcelona
Year: 2017
Authors:

Vande Casteele N.*1,2, Jairath V.3,4, Levesque B.1,2, Feagan B.3,4, Sandborn W.1,2

1University of California, San Diego, United States 2Robarts Clinical Trials, Inc., San Diego, United States 3University of Western Ontario, London, Canada 4Robarts Clinical Trials, Inc., London, Canada